



Date: February 07, 2019

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Sub: Intimation regarding acquisition of the remaining shares of BACC Health Care Private Limited (“BACC”) by HealthCare Global Enterprises Limited (“the Company”)

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Scrip Code: NSE Scrip Code: HCG; BSE Scrip Code: 539787

This is to inform the stock exchanges that in accordance with the terms of the shareholders’ agreement dated March 22, 2013 between the Company, Dr. Kamini A. Rao (“**Dr. Rao**”) and BACC (“**SHA**”), the Company shall acquire the remaining 46,695 equity shares, constituting 49.9% of the share capital of BACC (“**Shares**”) from Dr. Rao. The Company currently holds 50.1% of the share capital of BACC, which it acquired in March, 2013. BACC operates fertility treatment centres under the brand “Milann”. Dr. Rao will continue to serve as the Medical Director of Milann.

On acquiring the Shares, BACC would become a wholly owned subsidiary of the Company.

Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015:

(a) *Name of the target entity, details in brief such as size, turnover, etc;*

BACC Healthcare Private Limited (“**BACC**”), a private limited company, CIN: U74140KA2002PTC030098 and registered office at No. 7, East Park Road Basement, Kumara Park East, Bengaluru - 560 001, Karnataka. BACC is subsidiary of the Company (which currently owns 50.1% of the share capital of BACC). BACC operates 8 fertility centres across India under “Milann” brand. BACC’s turnover was INR 669.03 Million as of March 31, 2018.

(b) *Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;*

BACC is a subsidiary of the Company, with the Company owning 50.1% of the share capital of BACC. Dr. Rao is a Director of BACC, but she is not a related party with reference to the Company and therefore this is not a related party transaction.



(c) Industry to which the entity being acquired belongs;

BACC operates fertility treatment centres under the brand “Milann”. It owns and operates clinics providing comprehensive reproductive medicine services including assisted reproduction, gynaecological endoscopy and fertility preservation.

(d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);

With the acquisition of the Shares, BACC will become a wholly owned subsidiary of the Company. BACC operates in the fertility treatment business and the Company has been operating this business since it acquired 50.1% of the share capital of BACC in March, 2013.

(e) Brief details of any governmental or regulatory approvals required for the acquisition;

Nil.

(f) Indicative time period for completion of the acquisition;

Indicative time period for completion of the acquisition is by end of Q2 FY 2019-20.

(g) Nature of consideration - whether cash consideration or share swap and details of the same;

The consideration would be paid in cash.


(h) Cost of acquisition or the price at which the shares are acquired;

The consideration would be determined and paid as per the SHA.

Kindly take on record and acknowledge receipt of this information.

Thanking you,

For **HealthCare Global Enterprise Limited**



Sunu Manuel
Company Secretary & Compliance Officer